New insulin GZR33 aims to improve diabetes control
NCT ID NCT07242664
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing a new long-acting insulin called GZR33 in 12 adults with type 1 diabetes. The goal is to see how well it controls blood sugar compared to an existing insulin, degludec, and to check its safety. Participants will receive both insulins at different times to compare their effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GZR33 (a long-acting insulin)
What this could lead to
If successful, this could lead to a new long-acting insulin option for people with type 1 diabetes, potentially offering similar or better blood sugar control with fewer injections.
What could go wrong
This is a very early Phase 1 trial with only 12 participants, so results may not apply to everyone. The new insulin may not work as well as expected or could cause unexpected side effects like low blood sugar.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES MELLITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Profil
RECRUITINGNeuss, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Profil Institut
RECRUITINGNeuss, 41460, Germany